中牧股份(600195.SH):子公司兩個產品獲得新獸藥註冊證書
格隆匯10月11日丨中牧股份(600195.SH)公佈,根據《獸藥管理條例》和《獸藥註冊辦法》規定,農業農村部審查批准公司的子公司湖北中牧安達藥業有限公司、中牧南京動物藥業有限公司分別與其他單位聯合申報的兩個產品(泰地羅新和泰地羅新注射液)為新獸藥,核發《新獸藥註冊證書》。
泰地羅新為大環內酯類抗生素,具有廣譜殺菌作用,對一些革蘭氏陽性和革蘭氏陰性細菌均具有抗菌活性,引起豬呼吸系統疾病的病原菌對本品尤其敏感,如胸膜肺炎放線桿菌、多殺性巴氏桿菌、支氣管敗血波氏桿菌、副豬嗜血桿菌以及溶血性曼海姆菌、睡眠嗜組織菌等。此次獲得新獸藥註冊證書將對豐富公司化藥產品序列,提升市場競爭力產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.